Anavex Life Sciences Corp (AVXL)

[Investor2014]

I wonder if the discussion on Material Transfer Agreement (MTA) and any default obligation to file a SEC form 8-K regarding outcome and completion, might be based in a simple mix up with a Material Definitive Agreement, which is the subject of an 8-K?

This is what we do know about the MTA:

Biogen will test Anavex’s lead drug candidate, ANAVEX 2-73 in an oligodendrocyte precursor cell (OPC) differentiation assay. A satisfactory result from the OPC assay study may lead to an in vivo remyelination study using a chemical demyelination model

If the MTA in addition contains terms that involve a licensing agreement that, if invoked based upon the outcome of testing the material, would have a significant impact on the financial situation and future prospects of Anavex and/or Biogen, then it would be a Material Definitive Agreement.

As such, I doubt that the MTA includes specific licensing terms with financial detail. More likely, in my opinion, the MTA may contain terms along the lines of committing to initiate discussions that may result in a Material Definitive Agreement and no doubt various clauses that protects the respective IP rights involved.

According to feedback received from Anavex IR by members of this board, the MTA is still active. A subsequent or current discussions resulting in some form of licensing/partner agreement will of course in due course become public knowledge.